28-Feb-2019 | S | Outcome of Board Meeting held on Thursday, 28th February, 2019
Generic Pharmasec Ltd has informed BSE that the Board of Directors at their meeting held on February 28, 2019 have subject to the approval of shareholders and stock exchange where the shares of the Company are listed, have decided as under:-
1. Sub-division of Equity Shares Equity Shares of the Company having a face value of Rs. 10/- each in the Share Capital of the Company be sub-divided into 10 (ten) Equity Shares having a face value of Re. 1/- each.
2. To convene Extra Ordinary General Meeting (EOGM) of the Company to be held on Saturday the March 30, 2019 and approved the notice pertaining to the same.
Trading Members of the Exchange are hereby informed that Generic Pharmasec Limited has fixed Record Date for sub division of equity shares of the company.
DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT
COMPANY NAME & CODE
Generic Pharmasec Limited
(531592)
RECORD DATE
12/04/2019
PURPOSE
Sub Division of existing equity shares from every ONE equity share of Rs.10/- each into Ten equity shares of Rs. 1/- each.
SUB-DIVIDED PAID-UP VALUE
Rs.1/-
SUB-DIVIDED PAID-UP VALUE W.E.F.
11/04/2019 DR- 011/2019-2020
Note:-
i. ISIN No. INE861N01028 of Rs.10/- paid up will not be valid for transactions done on the Exchange on
or after 11/04/2019.
ii. The new ISIN Number for Rs.1/- paid up will be informed to the market by a separate notice.
(As Per BSE Notice Dated on 02.04.2019) | 12-Apr-2019 | |
03-Jan-2024 | R | 1:1 Rights Issue of Equity Shares
Trading Members of the Exchange are hereby informed that GENPHARMASEC LTD has fixed Record date for the purpose of Rights Issue of Equity Shares of the Company. The transactions in the Equity Shares of the Company should be done on Ex-Rights basis with effect from the under mentioned date :-
DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT
COMPANY NAME & CODE
GENPHARMASEC LTD
(531592)
RECORD DATE
09.01.2024
PURPOSE
Issue of 1 (One) Equity Shares of Re.1/- each for cash at a premium of Rs.0.75 per Equity Share on Rights Basis for every 1 (One) Equity Share held.*
Ex-Right basis from Date & Sett. No.
09/01/2024 DR-692/2023-2024
*As per the Terms of the Payment : - Full amount of the Issue Price of Rs.1.75 per Rights Equity Share shall be payable at the time of Application
Trading Members of the Exchange are requested to take note of it.
(As Per BSE Notice Dated on 04.01.2024) | 09-Jan-2024 | 1:1 |
26-Apr-2024 | BC | Intimation under Regulation 30 of SEBI (LODR) Regulation, 2015 for Appointment of Whole Time Director of the company. | 26-Apr-2024 | |
26-Apr-2024 | BC | Intimation under Regulation 30 of SEBI (LODR) Regulation, 2015 for Appointment of Whole Time Director of the company. | 26-Apr-2024 | |
21-Mar-2024 | BC | Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/03/2024 inter alia to consider and approve 1. To consider and take on record the resignat | 27-Mar-2024 | |
27-Mar-2024 | BC | Pursuant to Reg. 30 of SEBI (LODR) Reg. 2015, we wish to inform you that Mr. Hardik Makwana is appointed as the Company Secretary and Compliance Officer of the Company w.e.f. 27th March, 2024. | 27-Mar-2024 | |
20-Mar-2024 | BC | Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/03/2024 inter alia to consider and approve 1. To Review the performance of Non-Independen | 26-Mar-2024 | |
No Dividends has been declared by GENERICPHARMASEC
No Bonus has been declared by GENERICPHARMASEC
Record Date12-Apr-2019
Split Date11-Apr-2019
Face Value (Before/After)10/1
RightsRecord Date01 Jan'1900
Ex-Rights Date01 Jan'1900
Premium(Rs.)1
Ratio1:1
Book Closure
26-Apr-2024 | - | Intimation under Regulation 30 of SEBI (LODR) Regulation, 2015 for Appointment of Whole Time Director of the company. |
26-Apr-2024 | - | Intimation under Regulation 30 of SEBI (LODR) Regulation, 2015 for Appointment of Whole Time Director of the company. |
27-Mar-2024 | - | Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/03/2024 inter alia to consider and approve 1. To consider and take on record the resignat |
27-Mar-2024 | - | Pursuant to Reg. 30 of SEBI (LODR) Reg. 2015, we wish to inform you that Mr. Hardik Makwana is appointed as the Company Secretary and Compliance Officer of the Company w.e.f. 27th March, 2024. |
26-Mar-2024 | - | Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/03/2024 inter alia to consider and approve 1. To Review the performance of Non-Independen |